Literature DB >> 12107023

An oncological view on the blood-testis barrier.

Joost Bart1, Harry J M Groen, Winette T A van der Graaf, Harry Hollema, N Harry Hendrikse, Willem Vaalburg, Dirk T Sleijfer, Elisabeth G E de Vries.   

Abstract

The function of the blood-testis barrier is to protect germ cells from harmful influences; thus, it also impedes the delivery of chemotherapeutic drugs to the testis. The barrier has three components: first, a physicochemical barrier consisting of continuous capillaries, Sertoli cells in the tubular wall, connected together with narrow tight junctions, and a myoid-cell layer around the seminiferous tubule. Second, an efflux-pump barrier that contains P-glycoprotein in the luminal capillary endothelium and on the myoid-cell layer; and multidrug-resistance associated protein 1 located basolaterally on Sertoli cells. Third, an immunological barrier, consisting of Fas ligand on Sertoli cells. Inhibition of P-glycoprotein function offers the opportunity to increase the delivery of cytotoxic drugs to the testis. In the future, visualisation of function in the blood-testis barrier may also be helpful to identify groups of patients in whom testis conservation is safe or to select drugs that are less harmful to fertility.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107023     DOI: 10.1016/s1470-2045(02)00776-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  33 in total

Review 1.  Organic and inorganic transporters of the testis: A review.

Authors:  David M Klein; Nathan J Cherrington
Journal:  Spermatogenesis       Date:  2015-01-07

2.  Report of an unusual case: testicular involvement of chronic myeloid leukemia 10 years after the complete response.

Authors:  Cem Nedim Yuceturk; Berat Cem Ozgur; Hasmet Sarici; Pelin Borcek; Onur Telli
Journal:  J Clin Diagn Res       Date:  2014-04-15

3.  Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors.

Authors:  Richard J P Brown; Paul J Peters; Catherine Caron; Maria Paz Gonzalez-Perez; Leanne Stones; Chiambah Ankghuambom; Kemebradikumo Pondei; C Patrick McClure; George Alemnji; Stephen Taylor; Paul M Sharp; Paul R Clapham; Jonathan K Ball
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

4.  Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET.

Authors:  Stephen D Scotti; Jennifer Laudadio
Journal:  J Radiol Case Rep       Date:  2009-08-01

5.  Blood-testis barrier dynamics are regulated by an engagement/disengagement mechanism between tight and adherens junctions via peripheral adaptors.

Authors:  Helen H N Yan; C Yan Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-05       Impact factor: 11.205

6.  The biology of cancer testis antigens: putative function, regulation and therapeutic potential.

Authors:  Elisabetta Fratta; Sandra Coral; Alessia Covre; Giulia Parisi; Francesca Colizzi; Riccardo Danielli; Hugues Jean Marie Nicolay; Luca Sigalotti; Michele Maio
Journal:  Mol Oncol       Date:  2011-02-18       Impact factor: 6.603

7.  Xenobiotic transporter expression along the male genital tract.

Authors:  David M Klein; Stephen H Wright; Nathan J Cherrington
Journal:  Reprod Toxicol       Date:  2014-05-09       Impact factor: 3.143

8.  Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients.

Authors:  Astrid A M van der Veldt; N Harry Hendrikse; Egbert F Smit; Martien P J Mooijer; Anneloes Y Rijnders; Winald R Gerritsen; Jacobus J M van der Hoeven; Albert D Windhorst; Adriaan A Lammertsma; Mark Lubberink
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

Review 9.  Testicular cell junction: a novel target for male contraception.

Authors:  Nikki P Y Lee; Elissa W P Wong; Dolores D Mruk; C Yan Cheng
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

Review 10.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.